The National Institutes of Health (NIH) has released a Notice of Funding Opportunity (NOFO) for Innovation Grants to Nurture Initial Translational Efforts (IGNITE). This initiative focuses on funding R61/R33 Phased Innovation Awards aimed at the characterization and efficacy studies of neurotherapeutic agents intended for treating neurological disorders. The R61 phase will support preparatory activities establishing feasibility, while the R33 phase will focus on detailed pharmacodynamic and in vivo efficacy studies. A strong biological rationale, preliminary data, and a well-defined progression plan are essential for applications. The funding opportunity requires a Plan for Enhancing Diverse Perspectives (PEDP) to foster inclusivity and innovation in research teams. Notably, applications must meet specific eligibility requirements, demonstrate rigor in experimental design, and define clear milestones for transitioning between funding phases. Projects are expected to align with the NIH's mission to translate research discoveries into therapies, ultimately advancing the field of neurology and improving patient outcomes. The total project duration cannot exceed three years, with a funding cap of $499,000 per year. This NOFO emphasizes collaboration, the importance of rigorous experimental design, and the incorporation of diverse perspectives in project teams.